4.3 Review

Individualized glycaemic targets and pharmacotherapy in type 2 diabetes

期刊

DIABETES & VASCULAR DISEASE RESEARCH
卷 10, 期 5, 页码 397-409

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/1479164113490765

关键词

Glycaemic targets; HbA(1c); type 2 diabetes; individualized therapy; Global Partnership

资金

  1. Bristol-Myers Squibb
  2. AstraZeneca LP
  3. Novartis Pharma AG

向作者/读者索取更多资源

The Global Partnership for Effective Diabetes Management, established to provide practical guidance to improve patient outcomes in diabetes, has developed and modified recommendations to improve glycaemic control in type 2 diabetes. The Global Partnership advocates an individualized therapeutic approach and, as part of the process to customize therapy, has previously identified specific type 2 diabetes patient subgroups that require special consideration. This article builds on earlier publications, expanding the scope of practical guidance to include newly diagnosed individuals with complications and women with diabetes in pregnancy. Good glycaemic control remains the cornerstone of managing type 2 diabetes, and plays a vital role in preventing or delaying the onset and progression of diabetic complications. Individualizing therapeutic goals and treatments to meet glycaemic targets safely and without delay remains paramount, in addition to a wider programme of care to reduce cardiovascular risk factors and improve patient outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据